In 2003 Sandra Hulsshof et al. hypothesized that CX3CL1 might influence tissue remodeling by MAP kinase activation; such remodeling is a pivotal event in the development of MS lesions. This evidence concerns the gene CX3CL1 and myeloid sarcoma.